{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:01:44Z","timestamp":1775059304225,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Nature Science Foundation of Shanxi Province","award":["202203021212022"],"award-info":[{"award-number":["202203021212022"]}]},{"name":"The Nature Science Foundation of Shanxi Province","award":["202203021222410"],"award-info":[{"award-number":["202203021222410"]}]},{"name":"The Nature Science Foundation of Shanxi Province","award":["202403021221342"],"award-info":[{"award-number":["202403021221342"]}]},{"name":"Taiyuan's \"Six Categories of Projects\" Research Program","award":["Z2025001"],"award-info":[{"award-number":["Z2025001"]}]},{"name":"Shanxi Provincial Clinical Medical Research Center for Skin and Immune Diseases","award":["202204010501001"],"award-info":[{"award-number":["202204010501001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03267-y","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:51:02Z","timestamp":1760507462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of SPRED1 mutation in melanoma"],"prefix":"10.1186","volume":"30","author":[{"given":"Hui","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixia","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"4","key":"3267_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/ddg.15053_g","volume":"21","author":"S Ugurel","year":"2023","unstructured":"Ugurel S, Gutzmer R. Melanom. J Dtsch Dermatol Ges. 2023;21(4):343\u20137.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"3267_CR2","first-page":"63","volume":"9","author":"K Saginala","year":"2021","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci. 2021;9(4):63.","journal-title":"Med Sci"},{"key":"3267_CR3","first-page":"11","volume":"481","author":"LL P\u00e9rez","year":"2019","unstructured":"P\u00e9rez LL, Bashline B. Skin cancer: melanoma. FP Essent. 2019;481:11\u20136.","journal-title":"FP Essent"},{"issue":"1","key":"3267_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02279-8","volume":"16","author":"MA Khan","year":"2025","unstructured":"Khan MA, Mazhar T, Ali MD, Khattak UF, Shahzad T, Saeed MM, et al. Automatic melanoma and non-melanoma skin cancer diagnosis using advanced adaptive fine-tuned convolution neural networks. Discov Oncol. 2025;16(1):645.","journal-title":"Discov Oncol"},{"issue":"10","key":"3267_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/md20100618","volume":"20","author":"CAA Ferraz","year":"2022","unstructured":"Ferraz CAA, Grougnet R, Nicolau E, Picot L, de Oliveira Junior RG. Carotenoids from marine microalgae as antimelanoma agents. Mar Drugs. 2022;20(10):618.","journal-title":"Mar Drugs"},{"issue":"2","key":"3267_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.70007","volume":"38","author":"I Ribaudo","year":"2025","unstructured":"Ribaudo I, Arbesman M, Ni Y, Isaacs J, Kennedy LB, Ko J, et al. Genetic landscape of mucosal melanoma: identifying pathogenic germline variants. Pigment Cell Melanoma Res. 2025;38(2):e70007.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"3267_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126395","volume":"22","author":"S Strashilov","year":"2021","unstructured":"Strashilov S, Yordanov A. Aetiology and pathogenesis of cutaneous melanoma: current concepts and advances. Int J Mol Sci. 2021;22(12):6395.","journal-title":"Int J Mol Sci"},{"key":"3267_CR8","doi-asserted-by":"crossref","unstructured":"McRee SK, Bayer AL, Pietruska J, Tsichlis PN, Hinds PW. AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis. bioRxiv [Preprint]. 2023 Aug 24:2023.08.24.554685.","DOI":"10.1101\/2023.08.24.554685"},{"issue":"2","key":"3267_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","volume":"20","author":"LA Fecher","year":"2008","unstructured":"Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008;20(2):183\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"3267_CR10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201097","volume":"218","author":"J Ablain","year":"2021","unstructured":"Ablain J, Liu S, Moriceau G, Lo RS, Zon LI. SPRED1 deletion confers resistance to MAPK inhibition in melanoma. J Exp Med. 2021;218(3):e20201097.","journal-title":"J Exp Med"},{"issue":"9","key":"3267_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/ng2113","volume":"39","author":"H Brems","year":"2007","unstructured":"Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39(9):1120\u20136.","journal-title":"Nat Genet"},{"issue":"5","key":"3267_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/onc.2013.587","volume":"34","author":"E Pasmant","year":"2015","unstructured":"Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, et al. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. Oncogene. 2015;34(5):631\u20138.","journal-title":"Oncogene"},{"issue":"2","key":"3267_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.7150\/ijms.27757","volume":"16","author":"J Sun","year":"2019","unstructured":"Sun J, Zhang J, Wang Y, Li Y, Zhang R. A pilot study of aberrant CpG island hypermethylation of SPRED1 in acute myeloloid leukemia. Int J Med Sci. 2019;16(2):324\u201330.","journal-title":"Int J Med Sci"},{"issue":"10","key":"3267_CR14","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s12033-023-00669-3","volume":"65","author":"Q Yuan","year":"2023","unstructured":"Yuan Q, Zhang Y, Li J, Zhang D, Yang W. Circ_TEX2 functions as a tumor suppressor in hepatoma via miR-96-5p\/SPRED1 axis. Mol Biotechnol. 2023;65(10):1679\u201392.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"3267_CR15","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019;10(1):3163.","journal-title":"Nat Commun"},{"issue":"6127","key":"3267_CR16","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358.","journal-title":"Science"},{"issue":"7","key":"3267_CR17","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell"},{"issue":"2","key":"3267_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251\u201363.","journal-title":"Cell"},{"issue":"9","key":"3267_CR19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44(9):1006\u201314.","journal-title":"Nat Genet"},{"issue":"6","key":"3267_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1541-7786.MCR-20-0839","volume":"19","author":"N Broit","year":"2021","unstructured":"Broit N, Johansson PA, Rodgers CB, Walpole ST, Newell F, Hayward NK, et al. Meta-analysis and systematic review of the genomics of mucosal melanoma. Mol Cancer Res. 2021;19(6):991\u20131004.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"3267_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.18632\/oncotarget.240","volume":"2","author":"WH Chappell","year":"2011","unstructured":"Chappell WH, Steelman LS, Long JM, et al. Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2(3):135\u201364.","journal-title":"Oncotarget"},{"issue":"11","key":"3267_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875\u201385.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"3267_CR23","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/sj.onc.1210392","volume":"26","author":"M Raman","year":"2007","unstructured":"Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26(22):3100\u201312.","journal-title":"Oncogene"},{"issue":"3","key":"3267_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.critrevonc.2015.08.021","volume":"96","author":"MS Carlino","year":"2015","unstructured":"Carlino MS, Long GV, Kefford RF, Rizos H. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Crit Rev Oncol Hematol. 2015;96(3):385\u201398.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3267_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114104","volume":"178","author":"LS Ferraz","year":"2020","unstructured":"Ferraz LS, Costa RTD, Costa CAD, Ribeiro CAJ, Arruda DC, Maria-Engler SS, et al. Targeting mitochondria in melanoma: interplay between MAPK signaling pathway and mitochondrial dynamics. Biochem Pharmacol. 2020;178:114104.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"3267_CR26","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s10147-024-02615-y","volume":"29","author":"T Hida","year":"2024","unstructured":"Hida T, Kato J, Idogawa M, Tokino T, Uhara H. Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data. Int J Clin Oncol. 2024;29(12):1984\u201398.","journal-title":"Int J Clin Oncol"},{"issue":"21\u201322","key":"3267_CR27","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1101\/gad.341222.120","volume":"34","author":"C Lorenzo","year":"2020","unstructured":"Lorenzo C, McCormick F. SPRED proteins and their roles in signal transduction, development, and malignancy. Genes Dev. 2020;34(21\u201322):1410\u201321.","journal-title":"Genes Dev"},{"issue":"2","key":"3267_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12104-017-9768-1","volume":"11","author":"S F\u00fchrer","year":"2017","unstructured":"F\u00fchrer S, Ahammer L, Ausserbichler A, Scheffzek K, Dunzendorfer-Matt T, Tollinger M. NMR resonance assignments of the EVH1 domain of neurofibromin\u2019s recruitment factor Spred1. Biomol NMR Assign. 2017;11(2):305\u20138.","journal-title":"Biomol NMR Assign"},{"issue":"3","key":"3267_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107909","volume":"32","author":"W Yan","year":"2020","unstructured":"Yan W, Markegard E, Dharmaiah S, Urisman A, Drew M, Esposito D, et al. Structural insights into the SPRED1-Neurofibromin-KRAS complex and disruption of SPRED1-Neurofibromin interaction by oncogenic EGFR. Cell Rep. 2020;32(3):107909.","journal-title":"Cell Rep"},{"issue":"12","key":"3267_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107969","volume":"300","author":"Y Hirata","year":"2024","unstructured":"Hirata Y, Brems H, Van der Auweraer S, Ohyagi M, Iizuka M, Mise-Omata S, et al. Legius syndrome mutations in the Ras-regulator SPRED1 abolish its membrane localization and potentially cause neurodegeneration. J Biol Chem. 2024;300(12):107969.","journal-title":"J Biol Chem"},{"issue":"4","key":"3267_CR31","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.21037\/tcr.2020.03.05","volume":"9","author":"Z He","year":"2020","unstructured":"He Z, Gong F, Liao J, Wang Q, Su Y, Chen C, et al. Spred-3 mutation and Ras\/Raf\/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line. Transl Cancer Res. 2020;9(4):2542\u201355.","journal-title":"Transl Cancer Res"},{"issue":"4","key":"3267_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.bbrc.2011.06.068","volume":"410","author":"XN Ma","year":"2011","unstructured":"Ma XN, Liu XY, Yang YF, Xiao FJ, Li QF, Yan J, et al. Regulation of human hepatocellular carcinoma cells by Spred2 and correlative studies on its mechanism. Biochem Biophys Res Commun. 2011;410(4):803\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3267_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fonc.2020.00204","volume":"10","author":"R Zhang","year":"2020","unstructured":"Zhang R, Zhang Y, Lu X, Xu W, Wang H, Mo W, et al. SPRED1 is downregulated and a prognostic biomarker in adult acute myeloid leukemia. Front Oncol. 2020;10:204.","journal-title":"Front Oncol"},{"issue":"2","key":"3267_CR34","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s13577-023-00855-0","volume":"36","author":"Y Liu","year":"2023","unstructured":"Liu Y, Fan X, Jiang C, Xu S. Spock2 and Spred1 function downstream of EZH2 to impede the malignant progression of lung adenocarcinoma in vitro and in vivo. Hum Cell. 2023;36(2):812\u201321.","journal-title":"Hum Cell"},{"issue":"45","key":"3267_CR35","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1038\/sj.onc.1209635","volume":"25","author":"T Yoshida","year":"2006","unstructured":"Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, et al. Spreds, inhibitors of the Ras\/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene. 2006;25(45):6056\u201366.","journal-title":"Oncogene"},{"issue":"1","key":"3267_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/atm-20-2081","volume":"9","author":"W Tan","year":"2021","unstructured":"Tan W, Lin Z, Chen X, Li W, Zhu S, Wei Y, et al. MiR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med. 2021;9(1):38.","journal-title":"Ann Transl Med"},{"issue":"20","key":"3267_CR37","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1128\/MCB.00191-16","volume":"36","author":"E Siljam\u00e4ki","year":"2016","unstructured":"Siljam\u00e4ki E, Abankwa D. SPRED1 interferes with K-ras but not H-ras membrane anchorage and signaling. Mol Cell Biol. 2016;36(20):2612\u201325.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"3267_CR38","first-page":"11","volume":"27","author":"DC Goldemberg","year":"2019","unstructured":"Goldemberg DC, Thuler LCS, de Melo AC. An update on mucosal melanoma: future directions. Acta Dermatovenerol Croat. 2019;27(1):11\u20135.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"8","key":"3267_CR39","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/BF02303485","volume":"5","author":"P DeMatos","year":"1998","unstructured":"DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol. 1998;5(8):733\u201342.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"3267_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cps.2021.05.010","volume":"48","author":"D Olla","year":"2021","unstructured":"Olla D, Neumeister MW. Mucosal melanoma. Clin Plast Surg. 2021;48(4):707\u201311.","journal-title":"Clin Plast Surg"},{"issue":"5","key":"3267_CR41","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jaad.2006.06.017","volume":"56","author":"RJ Patrick","year":"2007","unstructured":"Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56(5):828\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"3267_CR42","first-page":"739","volume":"5","author":"M Mihajlovic","year":"2012","unstructured":"Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol. 2012;5(8):739\u201353.","journal-title":"Int J Clin Exp Pathol"},{"issue":"8","key":"3267_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081133","volume":"11","author":"N Dumaz","year":"2019","unstructured":"Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebb\u00e9 C. Atypical BRAF and NRAS mutations in mucosal melanoma. Cancers (Basel). 2019;11(8):1133.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3267_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/CMR.0000000000000116","volume":"25","author":"N Dumaz","year":"2015","unstructured":"Dumaz N, Andr\u00e9 J, Sadoux A, Laugier F, Podgorniak MP, Mourah S, et al. Driver KIT mutations in melanoma cluster in four hotspots. Melanoma Res. 2015;25(1):88\u201390.","journal-title":"Melanoma Res"},{"issue":"6418","key":"3267_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1126\/science.aau6509","volume":"362","author":"J Ablain","year":"2018","unstructured":"Ablain J, Xu M, Rothschild H, Jordan RC, Mito JK, Daniels BH, et al. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Science. 2018;362(6418):1055\u201360.","journal-title":"Science"},{"issue":"7463","key":"3267_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"7","key":"3267_CR47","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"CGA Network","year":"2015","unstructured":"Network CGA. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396.","journal-title":"Cell"},{"issue":"7653","key":"3267_CR48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Mann GJ, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175\u201380.","journal-title":"Nature"},{"issue":"9","key":"3267_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092241","volume":"13","author":"EL Thompson","year":"2021","unstructured":"Thompson EL, Hu JJ, Niedernhofer LJ. The role of senescent cells in acquired drug resistance and secondary cancer in BRAFi-treated melanoma. Cancers (Basel). 2021;13(9):2241.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3267_CR50","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/s41419-022-05365-9","volume":"13","author":"R Cristofani","year":"2022","unstructured":"Cristofani R, Piccolella M, Montagnani Marelli M, Tedesco B, Poletti A, Moretti RM. HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy. Cell Death Dis. 2022;13(11):973.","journal-title":"Cell Death Dis"},{"issue":"2","key":"3267_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000381849","volume":"231","author":"M Baiter","year":"2015","unstructured":"Baiter M, Schuler G, Hartmann A, Schneider-Stock R, Heinzerling L. Pathogenetic implications of BRAF mutation distribution in stage IV melanoma patients. Dermatology. 2015;231(2):127\u201333.","journal-title":"Dermatology"},{"issue":"5","key":"3267_CR52","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bjd.12504","volume":"169","author":"H Ekedahl","year":"2013","unstructured":"Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol. 2013;169(5):1049\u201355.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3267_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CMR.0000000000000630","volume":"30","author":"KA Malkhasyan","year":"2020","unstructured":"Malkhasyan KA, Rooney SL, Snow AN, Swick BL, Milhem MM, Zakharia Y. The clinical characteristics of melanoma with BRAF V600R mutation: a case series study. Melanoma Res. 2020;30(1):107\u201312.","journal-title":"Melanoma Res"},{"issue":"7315","key":"3267_CR54","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596\u20139.","journal-title":"Nature"},{"issue":"9","key":"3267_CR55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809\u201319.","journal-title":"N Engl J Med"},{"issue":"26","key":"3267_CR56","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"9839","key":"3267_CR57","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358\u201365.","journal-title":"Lancet"},{"issue":"3","key":"3267_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332.","journal-title":"Lancet Oncol"},{"issue":"22","key":"3267_CR59","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085\u201396.","journal-title":"J Clin Oncol"},{"issue":"7326","key":"3267_CR60","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen CM, Boehm JS, Kim SY, et al. Cot drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968\u201372.","journal-title":"Nature"},{"issue":"7326","key":"3267_CR61","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973\u20137.","journal-title":"Nature"},{"key":"3267_CR62","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/ncomms1727","volume":"3","author":"H Shi","year":"2012","unstructured":"Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.","journal-title":"Nat Commun"},{"issue":"50","key":"3267_CR63","doi-asserted-by":"publisher","first-page":"52543","DOI":"10.1074\/jbc.M405189200","volume":"279","author":"A Nonami","year":"2004","unstructured":"Nonami A, Kato R, Taniguchi K, et al. Spred-1 negatively regulates interleukin-3-mediated ERK\/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. J Biol Chem. 2004;279(50):52543\u201351.","journal-title":"J Biol Chem"},{"issue":"6847","key":"3267_CR64","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/35088082","volume":"412","author":"T Wakioka","year":"2001","unstructured":"Wakioka T, Sasaki A, Kato R, et al. Spred is a sprouty-related suppressor of Ras signalling. Nature. 2001;412(6847):647\u201351.","journal-title":"Nature"},{"issue":"13","key":"3267_CR65","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1101\/gad.190876.112","volume":"26","author":"IB Stowe","year":"2012","unstructured":"Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hern\u00e1ndez H, et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 2012;26(13):1421\u20136.","journal-title":"Genes Dev"},{"issue":"2","key":"3267_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111942","volume":"390","author":"K Zhao","year":"2020","unstructured":"Zhao K, Lu Y, Chen Y, Cheng J, Zhang W. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells. Exp Cell Res. 2020;390(2):111942.","journal-title":"Exp Cell Res"},{"issue":"7","key":"3267_CR67","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/ijms18071550","volume":"18","author":"F Bootorabi","year":"2017","unstructured":"Bootorabi F, Manouchehri H, Changizi R, et al. Zebrafish as a model organism for the development of drugs for skin cancer. Int J Mol Sci. 2017;18(7):1550.","journal-title":"Int J Mol Sci"},{"key":"3267_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.854192","volume":"12","author":"N Su","year":"2022","unstructured":"Su N, Wang Y, Lu X, Xu W, Wang H, Mo W, et al. Methylation of SPRED1: a new target in acute myeloid leukemia. Front Oncol. 2022;12:854192.","journal-title":"Front Oncol"},{"issue":"11","key":"3267_CR69","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/humu.22152","volume":"33","author":"H Brems","year":"2012","unstructured":"Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E, et al. Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat. 2012;33(11):1538\u201346.","journal-title":"Hum Mutat"},{"issue":"5","key":"3267_CR70","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s11684-023-1004-z","volume":"17","author":"P Zhao","year":"2023","unstructured":"Zhao P, Wang Y, Yu X, Nan Y, Liu S, Li B, et al. Long noncoding RNA LOC646029 functions as a ceRNA to suppress ovarian cancer progression through the miR-627-3p\/SPRED1 axis. Front Med. 2023;17(5):924\u201338.","journal-title":"Front Med"},{"issue":"10","key":"3267_CR71","first-page":"1","volume":"66","author":"W Liu","year":"2020","unstructured":"Liu W, Fang S, Zuo G. A study on the expression of SPRED1 and PBRM1 (Baf180) and their clinical significances in patients with gastric cancer. Clin Lab. 2020;66(10):1.","journal-title":"Clin Lab"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03267-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T07:02:54Z","timestamp":1760511774000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03267-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3267"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03267-y","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"973"}}